Nisa Investment Advisors LLC Purchases 13,867 Shares of DexCom, Inc. (NASDAQ:DXCM)

Nisa Investment Advisors LLC grew its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 23.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,232 shares of the medical device company's stock after purchasing an additional 13,867 shares during the period. Nisa Investment Advisors LLC's holdings in DexCom were worth $5,773,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Perfromance Wealth Partners LLC grew its position in DexCom by 4.2% during the 4th quarter. Perfromance Wealth Partners LLC now owns 34,996 shares of the medical device company's stock worth $2,722,000 after acquiring an additional 1,420 shares during the last quarter. Mitsubishi UFJ Asset Management UK Ltd. grew its holdings in shares of DexCom by 500.0% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 6,000 shares of the medical device company's stock worth $467,000 after purchasing an additional 5,000 shares during the last quarter. Atomi Financial Group Inc. increased its stake in shares of DexCom by 36.5% in the fourth quarter. Atomi Financial Group Inc. now owns 5,374 shares of the medical device company's stock valued at $418,000 after buying an additional 1,438 shares during the period. Ballentine Partners LLC bought a new position in DexCom in the 4th quarter valued at approximately $215,000. Finally, MassMutual Private Wealth & Trust FSB boosted its position in DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock worth $65,000 after buying an additional 265 shares during the period. 97.75% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several analyst reports. Canaccord Genuity Group raised their price target on shares of DexCom from $89.00 to $99.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup lifted their target price on DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Raymond James decreased their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research note on Friday, October 25th. Finally, Leerink Partners cut their price objective on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $99.29.

DexCom Stock Up 1.2 %

Shares of DXCM traded up $1.05 during trading hours on Friday, hitting $88.75. The stock had a trading volume of 3,256,153 shares, compared to its average volume of 2,929,114. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The firm has a market capitalization of $34.67 billion, a P/E ratio of 53.14, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. The firm has a 50 day simple moving average of $79.50 and a 200-day simple moving average of $77.35. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.30% of the company's stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.